Abstract
Background: The role of adjuvant therapy in pancreatic cancer remains controversial. Gemcitabine given systemically seems to be effective; intra-arterial chemotherapy (IAC) has a deep rationale. Patients and methods: The goal was to evaluate the impact of postoperative IAC followed or not by systemic gemcitabine in patients after curative resection for pancreatic adenocarcinoma. 5-fluoruracil 750 mg sqm−1, leucovorin 75 mg sqm−1, epirubicin 45 mg sqm−1, carboplatin 225 mg sqm−1 were administered every 3 weeks into celiac axis for three cycles (FLEC regimen), then gemcitabine at the dosage of 1 g sqm−1 on days 1, 8 and 15 every 4 weeks for 3 months (FLECG regimen). Results: Forty-seven patients entered the study. The first 24 received only IAC (FLEC regimen), the other 23 received the same intra-arterial regimen followed by systemic gemcitabine (FLECG regimen). After a median follow-up of 16.9 months, 29 patients recurred (61.7%). Median disease free survival (DFS) was 18 months and median overall survival (OS) was 29.7 months. One-year DFS was 59.4% and 1-year OS was 75.5%. Main grade 3 toxicity related to IAC was only nausea/vomiting in 4%; regarding gemcitabine, grade 3 toxicities were anaemia 8%, leukopenia 8%, thrombocitopenia 17%, nausea/vomiting 4%. Conclusions: FLEC regimen with or without gemcitabine is active with a very mild toxicity and results are very encouraging in an adjuvant setting.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Griffin JF, Smalley SR, Jewell W et al (1990) Patterns of failure following curative resection of pancreatic carcinoma. Cancer 66(1):56–61
Foo ML, Gunderson LL, Nagorney DM et al (1993) Patterns of failure in grossly resected pancreatic ductal adenocarcinoma treated with adjuvant irradiation +/− 5-fluoruracil. Int J Radiat Oncol Biol Phys 26(3):483–489
Yeo CJ, Cameron JL, Lillemoe KD et al (2002) Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma. Randomized controlled trial evaluating survival, morbidity and mortality. Ann Surg 236(3):355–366
Gastrointestinal Tumor Study Group (1987) Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer 59(12):2006–2010
Neoptolemos JP, Stocken DD, Friess H et al (2004) A randomized trial of chemotherapy after resection of pancreatic cancer. N Engl J Med 350(12):1200–1210
Neuhaus P, Oettle H, Post S et al (2005) A randomised, prospectic, multicenter, phase III trial of adjuvant chemotherapy with gemcitabine vs observation in patients with resected pancreatic cancer. Proc Am Soc Clin Oncol 23 (abstr 4013)
Link KH, Gansauge F, Gorich J et al (1997) Palliative and adjuvant regional chemotherapy in pancreatic cancer. Eur J Surg Oncol 23(5):409–414
Muchmore JH, Carter RD, Preslan JE et al (1996) Regional chemotherapy with hemofiltration: a rationale for a different treatment approach to advanced pancreatic cancer. Hepatogastroenterology 43(8):346–355
Cantore M, Pederzoli P, Cornalba G et al (2000) Intra-arterial chemotherapy for unresectable pancreatic cancer. Ann Oncol 11:569–573
Link KH, Gansuage F, Rilinger N et al (1997) Celiac artery adjuvant chemotherapy: results of a prospective trial. Int J Pancreatol 21(1):65–69
Ishikawa O, Ohigashi H, Sasaki et al (1994) Liver perfusion chemotherapy via both the hepatic artery and portal vein to prevent hepatic metastasis after extended pancreatectomy for adenocarcinoma of the pancreas. Am J Surg 168(4):361–364
Papachristou E, Link KH, Scoenberg MH et al (2003) Regional celiac artery infusion in the adjuvant treatment of pancreatic cancer. Anticancer Res 23(2A):831–834
Adjani IA, Welch SR, Raber MN et al (1990) Comprehensive criteria for assessing therapy-induced toxicity. Cancer Invest 8(2):147–159
Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trial 10(1):1–10
Picozzi VJ, Kozarek RA, Traverso LW (2003) Interferon-based chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am J Surg 185(5):476–480
Reni M, Passoni P, Bonetto E et al (2005) Final results of a prospective trial of a PEFG (Cisplatin, Epirubicin, 5-fluoruracil, Gemcitabine) regimen followed by radiotherapy after curative surgery for pancreatic adenocarcinoma. Oncology 68(2–3):239–245
Reni M, Cordio S, Milandri C et al (2005) Gemcitabine versus cisplatin, epirubicin, fluoruracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial. Lancet Oncol 6(6):369–376
Moore MJ, Goldstein D, Hamm J et al (2005) Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase II trial of the National Cancer Institute Clinical trials Group. Proc Am Soc Clin Oncol 23:(Abstr1)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Cantore, M., Serio, G., Pederzoli, P. et al. Adjuvant intra-arterial 5-fluoruracil, leucovorin, epirubicin and carboplatin with or without systemic gemcitabine after curative resection for pancreatic adenocarcinoma. Cancer Chemother Pharmacol 58, 504–508 (2006). https://doi.org/10.1007/s00280-006-0200-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-006-0200-2